Spotlight on Hematology
Optimizing Treatment of B-Cell Non-Hodgkin Lymphomas in the Modern Era - Part B
StartActivity Details
0.5 Contact Hour(s)
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with B-Cell Non-Hodgkin Lymphomas.
Learning Objectives
After completing this program, participants should be able to:
- Summarize current evidence-based management strategies for treating B-cell NHLs with newer agents and combination approaches
- Evaluate safety and efficacy data from recent clinical trials and its impact on future clinical practice
- Formulate individualized strategies for incorporating new agents and regimens into the evolving treatment paradigms for B-cell NHLs, taking into consideration current guidelines, expert recommendations, and clinical factors
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of B-Cell Non-Hodgkin Lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for B-Cell Non-Hodgkin Lymphomas along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with B-Cell Non-Hodgkin Lymphomas, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Co-Director Lymphoma Program
Winship Cancer Institute
Emory University
Atlanta, GA
Conflict of Interest Policy/Disclosure Statement
Dr. Cohen has served on advisory boards for Janssen and Genentech and has done research funding for Genentech.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by educational grant from AbbVie Inc., Bayer HealthCare Pharmaceutical Inc., Celgene Corp., Janssen Biotech, Inc., and Verastem.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions about the Activity
Activity Details
0.5 Contact Hour(s)
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with B-Cell Non-Hodgkin Lymphomas.
Learning Objectives
After completing this program, participants should be able to:
- Summarize current evidence-based management strategies for treating B-cell NHLs with newer agents and combination approaches
- Evaluate safety and efficacy data from recent clinical trials and its impact on future clinical practice
- Formulate individualized strategies for incorporating new agents and regimens into the evolving treatment paradigms for B-cell NHLs, taking into consideration current guidelines, expert recommendations, and clinical factors
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of B-Cell Non-Hodgkin Lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for B-Cell Non-Hodgkin Lymphomas along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with B-Cell Non-Hodgkin Lymphomas, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Co-Director Lymphoma Program
Winship Cancer Institute
Emory University
Atlanta, GA
Conflict of Interest Policy/Disclosure Statement
Dr. Cohen has served on advisory boards for Janssen and Genentech and has done research funding for Genentech.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by educational grant from AbbVie Inc., Bayer HealthCare Pharmaceutical Inc., Celgene Corp., Janssen Biotech, Inc., and Verastem.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions about the Activity
Hematology Presentations
Multiple Myeloma Practicums: Caring for Patients in an Ever-Changing Treatment Environment
StartActivity Details
Expires: December 14, 2021
Accredited By
The University of Nebraska Medical Center, Center for Continuing
Education
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.
Learning Objectives
After participating in this activity, participants should be better able to:
- Evaluate various frontline treatment options that are available for the treatment of patients with newly diagnosed MM
- Discuss maintenance therapy options that may be appropriate for patients with MM
- Assess strategies for proper sequencing of agents and regimens in patients with progressive disease
- Review common adverse events that are associated with various treatment strategies and approaches to mitigating such adverse events
Activity Description
This activity will provide expert guidance regarding the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents. It is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs.
Statement of Educational Need
Major advances in the diagnosis and treatment of MM have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. As we go forward with these strategies, clinicians treating patients with MM need expert guidance to evaluate best practices and emerging clinical data and plan strategies to apply them safely and effectively to their patients.
Faculty
Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Atlanta, Georgia
Disclosures
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis.
Conflict of Interest Policy/Disclosure Statement
Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
All disclosed conflicts of interest have been resolved by independent content review.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.
Accreditation Statement
Continuing Education
The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Statement of Commercial Support
This activity is supported by independent educational grants from GlaxoSmithKline, Janssen, and Oncopeptides.
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Contact Information for Questions About the Activity
info@bioascend.com
Activity Details
Expires: December 14, 2021
Accredited By
The University of Nebraska Medical Center, Center for Continuing
Education
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.
Learning Objectives
After participating in this activity, participants should be better able to:
- Evaluate various frontline treatment options that are available for the treatment of patients with newly diagnosed MM
- Discuss maintenance therapy options that may be appropriate for patients with MM
- Assess strategies for proper sequencing of agents and regimens in patients with progressive disease
- Review common adverse events that are associated with various treatment strategies and approaches to mitigating such adverse events
Activity Description
This activity will provide expert guidance regarding the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents. It is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs.
Statement of Educational Need
Major advances in the diagnosis and treatment of MM have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. As we go forward with these strategies, clinicians treating patients with MM need expert guidance to evaluate best practices and emerging clinical data and plan strategies to apply them safely and effectively to their patients.
Faculty
Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Atlanta, Georgia
Disclosures
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis.
Conflict of Interest Policy/Disclosure Statement
Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
All disclosed conflicts of interest have been resolved by independent content review.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.
Accreditation Statement
Continuing Education
The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Statement of Commercial Support
This activity is supported by independent educational grants from GlaxoSmithKline, Janssen, and Oncopeptides.
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Contact Information for Questions About the Activity
info@bioascend.com
Diagnosis of Thrombotic Thrombocytopenic Purpura (TTP)
StartActivity Details
Expires: December 13, 2021
Accredited By
Target Audience
This activity is intended for hematologists, emergency medicine physicians, critical care physicians, and primary care providers.
Learning Objectives
Upon completion of this course, the participants should be able to:
- Differentiate acquired TTP from hereditary TTP
- Recognize cardinal features in the presentation of TTP
- Diagnose TTP accurately using recommended tests
- Distinguish between TTP and other disorders in a differential diagnosis
Statement of Educational Need
Given the recent updates in research, progress in diagnosis and treatment, and the rarity of TTP and its associated 90%+ mortality rate if untreated, it is imperative that physicians become conversant with the disorder and the new information associated with its recognition, diagnosis, and treatment.
Faculty
Head, Division of Transfusion Medicine
St. Michael’s Hospital
University of Toronto
Toronto, Canada
Katerina Pavenski, MD, FRCPC, has served as a consultant for Alexion, Sanofi, and Takeda. She has received contract research support from Sanofi.
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, TFF and the ISTH require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and the ISTH resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and the ISTH seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and the ISTH are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation (TFF) and the International Society on Thrombosis and Haemostasis (ISTH). TFF is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Physicians
TFF designates this enduring activity for a maximum of
0.50 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Nurses
Nurses certified by the American Nurses Credentialing Center (ANCC) may
utilize activities that are certified by ACCME-accredited providers toward
their requirement for certification renewal by the ANCC. A certificate of
attendance will be provided by TFF, an ACCME-accredited provider.
Instructions for Receiving Credit
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity.
- Complete the online posttest. A score of 100% is required to complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form. This form provides each participant the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
Statement of Commercial Support
This activity is supported by educational grants from Shire and Sanofi Genzyme.
Disclaimer Statement/Disclosure of Unlabeled Use
TFF and the ISTH present this information for educational purposes only. The content is provided solely by faculty who have been selected for their recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. TFF, the ISTH, and the commercial supporter(s) assume no liability for the information herein.
TFF and the ISTH require CME faculty (speakers) to disclose when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational. This includes any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration-approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and the ISTH do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Activity Details
Expires: December 13, 2021
Accredited By
Target Audience
This activity is intended for hematologists, emergency medicine physicians, critical care physicians, and primary care providers.
Learning Objectives
Upon completion of this course, the participants should be able to:
- Differentiate acquired TTP from hereditary TTP
- Recognize cardinal features in the presentation of TTP
- Diagnose TTP accurately using recommended tests
- Distinguish between TTP and other disorders in a differential diagnosis
Statement of Educational Need
Given the recent updates in research, progress in diagnosis and treatment, and the rarity of TTP and its associated 90%+ mortality rate if untreated, it is imperative that physicians become conversant with the disorder and the new information associated with its recognition, diagnosis, and treatment.
Faculty
Head, Division of Transfusion Medicine
St. Michael’s Hospital
University of Toronto
Toronto, Canada
Katerina Pavenski, MD, FRCPC, has served as a consultant for Alexion, Sanofi, and Takeda. She has received contract research support from Sanofi.
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, TFF and the ISTH require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and the ISTH resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and the ISTH seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and the ISTH are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation (TFF) and the International Society on Thrombosis and Haemostasis (ISTH). TFF is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Physicians
TFF designates this enduring activity for a maximum of
0.50 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Nurses
Nurses certified by the American Nurses Credentialing Center (ANCC) may
utilize activities that are certified by ACCME-accredited providers toward
their requirement for certification renewal by the ANCC. A certificate of
attendance will be provided by TFF, an ACCME-accredited provider.
Instructions for Receiving Credit
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity.
- Complete the online posttest. A score of 100% is required to complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form. This form provides each participant the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
Statement of Commercial Support
This activity is supported by educational grants from Shire and Sanofi Genzyme.
Disclaimer Statement/Disclosure of Unlabeled Use
TFF and the ISTH present this information for educational purposes only. The content is provided solely by faculty who have been selected for their recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. TFF, the ISTH, and the commercial supporter(s) assume no liability for the information herein.
TFF and the ISTH require CME faculty (speakers) to disclose when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational. This includes any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration-approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and the ISTH do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Integrating New Treatment Options for B-Cell Non-Hodgkin Lymphomas into Practice
StartActivity Details
1.0 Contact Hour(s)
Expires: December 9, 2021
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with B-Cell Non-Hodgkin Lymphomas.
Learning Objectives
After completing this program, participants should be able to:
- Differentiate among emerging and recently approved therapies for B-cell NHLs and review the considerations for their clinical use
- Assess the latest clinical data on new and emerging approaches for treating B-cell NHLs in order to best integrate them into care
- Formulate individualized, evidence-based best-practice treatment plans for patients with B-cell NHLs
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of B-Cell Non-Hodgkin Lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
NHL is one of the most common cancers in the United States, accounting for about 4% of all cancers. This heterogenous group of lymphoproliferative disorders remains a challenge to treat due to differing patterns of behavior and responses to treatment. The ever-changing treatment landscape of NHL provides clinicians new and potentially efficacious approaches with which to treat these challenging cases but selecting a treatment that meets both the clinician’s and the patient’s goals remains challenging. As such, healthcare professionals treating patients with B-cell malignancies will require competency in understanding the application, efficacy, and safety of these new and emerging treatment options to provide sufficient care, support, and treatment.
Faculty
Director of Lymphoma Research Program
Sarah Cannon Research Institute
Tennessee Oncology/OneOncology
Nashville, TN
Conflict of Interest Policy/Disclosure Statement
Dr. Flinn has consulted for:
AbbVie, AstraZeneca, BeiGene, Curio Science, Gilead Science, Great Point
Partners, Iksuda Therapeutics, Janssen, Juno Therapeutics, Kite Pharma,
MorphoSys, Nurix Therapeutics, Pharmacyclics, Roche, Seattle Genetics,
Takeda, TG Therapeutics, Unum Therapeutics, Verastem, Vincera Pharma, Yingli
Pharmaceuticals.
Dr. Flinn has research grants from:
AbbVie, Acerta Pharma, Agios, ArQule, AstraZeneca, BeiGene, Calithera
Biosciences, Celgene, Constellation Pharmaceuticals, Curis, F. Hofman-la
Roche Ltd, Forma Therapeutics, Forty Seven, Genentech, Gilead Sciences, IGM
Biosciences, Incyte, Infinity Pharmaceuticals, Janssen, Juno Therapeutics,
Karyopharm, KITE Pharma, Loxo, Merck, MorphoSys, Novartis, Pfizer,
Pharmacyclics, Portola Pharmaceuticals, Rhizen Pharmaceuticals, Roche,
Seattle Genetics, Takeda, Teva, TG Therapeutics, Trillium Therapeutics,
Triphase Research & Development Corp., Unum Therapeutics, Verastem.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity is being presented without bias and with commercial support.
Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by an educational grant from BMS, Epizyme, Inc. and Janssen Biotech, Inc.
Disclaimer Statement/ Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Activity Details
1.0 Contact Hour(s)
Expires: December 9, 2021
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with B-Cell Non-Hodgkin Lymphomas.
Learning Objectives
After completing this program, participants should be able to:
- Differentiate among emerging and recently approved therapies for B-cell NHLs and review the considerations for their clinical use
- Assess the latest clinical data on new and emerging approaches for treating B-cell NHLs in order to best integrate them into care
- Formulate individualized, evidence-based best-practice treatment plans for patients with B-cell NHLs
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of B-Cell Non-Hodgkin Lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
NHL is one of the most common cancers in the United States, accounting for about 4% of all cancers. This heterogenous group of lymphoproliferative disorders remains a challenge to treat due to differing patterns of behavior and responses to treatment. The ever-changing treatment landscape of NHL provides clinicians new and potentially efficacious approaches with which to treat these challenging cases but selecting a treatment that meets both the clinician’s and the patient’s goals remains challenging. As such, healthcare professionals treating patients with B-cell malignancies will require competency in understanding the application, efficacy, and safety of these new and emerging treatment options to provide sufficient care, support, and treatment.
Faculty
Director of Lymphoma Research Program
Sarah Cannon Research Institute
Tennessee Oncology/OneOncology
Nashville, TN
Conflict of Interest Policy/Disclosure Statement
Dr. Flinn has consulted for:
AbbVie, AstraZeneca, BeiGene, Curio Science, Gilead Science, Great Point
Partners, Iksuda Therapeutics, Janssen, Juno Therapeutics, Kite Pharma,
MorphoSys, Nurix Therapeutics, Pharmacyclics, Roche, Seattle Genetics,
Takeda, TG Therapeutics, Unum Therapeutics, Verastem, Vincera Pharma, Yingli
Pharmaceuticals.
Dr. Flinn has research grants from:
AbbVie, Acerta Pharma, Agios, ArQule, AstraZeneca, BeiGene, Calithera
Biosciences, Celgene, Constellation Pharmaceuticals, Curis, F. Hofman-la
Roche Ltd, Forma Therapeutics, Forty Seven, Genentech, Gilead Sciences, IGM
Biosciences, Incyte, Infinity Pharmaceuticals, Janssen, Juno Therapeutics,
Karyopharm, KITE Pharma, Loxo, Merck, MorphoSys, Novartis, Pfizer,
Pharmacyclics, Portola Pharmaceuticals, Rhizen Pharmaceuticals, Roche,
Seattle Genetics, Takeda, Teva, TG Therapeutics, Trillium Therapeutics,
Triphase Research & Development Corp., Unum Therapeutics, Verastem.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity is being presented without bias and with commercial support.
Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by an educational grant from BMS, Epizyme, Inc. and Janssen Biotech, Inc.
Disclaimer Statement/ Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
The Expanding Role of BTK Inhibitors for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
StartThe Expanding Role of BTK Inhibitors for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
Activity Details
Expires: December 7, 2021
Accredited By
The University of Nebraska Medical Center, Center for Continuing
Education
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with CLL.
Learning Objectives
After participating in this activity, participants should be better able to:
- Identify the role of BTK signaling in the pathogenesis of CLL, and the rationale for targeting BTK in patients with this malignancy
- Assess clinical trial data of BTK inhibitors that are currently approved for the treatment of patients with CLL
- Evaluate emerging clinical trial data of current and novel BTK inhibitors, including monotherapy and combination approaches
- Review strategies for improving patient outcomes, including optimal selection and sequencing of therapy, as well as oral adherence strategies
Activity Description
Bruton’s tyrosine kinase (BTK) inhibitors are an evolving therapeutic strategy for the treatment of patients with CLL. With multiple BTK inhibitors (and combinations) under investigation and pending approval, clinicians need expert guidance to correctly use these agents safely and effectively for patients with CLL, and plan strategies for optimal integration of these novel agents into practice. This webcast will provide expert interpretation of emerging data and guidance regarding patient diagnosis, treatment, maintenance therapy, and sequencing of agents.
Statement of Educational Need
BTK inhibitors have substantially altered the management, clinical course, and outcome of patients with CLL. This is especially true for patients with previously limited treatment options due to disease characteristics or coexisting diseases. Ibrutinib was the first orally available, nonselective and irreversible inhibitor of BTK approved for the treatment of patients with various B-cell malignancies. Newer and more selective BTK inhibitors are currently in clinical development, including acalabrutinib, which is currently US FDA approved for previously treated mantle cell lymphoma. Significant efforts are underway to investigate the optimal combinations, timing, and sequencing of BTK inhibitors with other regimens and targeted agents, and to capitalize on the immunomodulatory modes of action of BTK inhibitors to correct tumor-induced immune defects and to achieve long-lasting tumor control.
Faculty
Associate Professor of Medicine
Harvard Medical Center
Associate Director, Center for Chronic Lymphocytic Leukemia
Dana-Farber Cancer Institute
Boston, Massachusetts
Disclosures
Contracted Research & Publishing: AbbVie Inc., Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma Inc., Pharmacyclics LLC, Surface Oncology, TG Therapeutics, Verastem, Inc.
Consulting Fees: AbbVie Inc., Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Celgene Corporation, Genentech, Janssen, MEI Pharma Inc., Pharmacyclics LLC, Research to Practice, TG Therapeutics, Verastem, Inc.
Conflict of Interest Policy/Disclosure Statement
Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
All disclosed conflicts of interest have been resolved by independent content review.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.
Accreditation Statement
Continuing Education
The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Statement of Commercial Support
This activity is supported by independent educational grants from AstraZeneca, BeiGene and Pharmacyclics.
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Contact Information for Questions About the Activity
info@bioascend.com
The Expanding Role of BTK Inhibitors for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
Activity Details
Expires: December 7, 2021
Accredited By
The University of Nebraska Medical Center, Center for Continuing
Education
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with CLL.
Learning Objectives
After participating in this activity, participants should be better able to:
- Identify the role of BTK signaling in the pathogenesis of CLL, and the rationale for targeting BTK in patients with this malignancy
- Assess clinical trial data of BTK inhibitors that are currently approved for the treatment of patients with CLL
- Evaluate emerging clinical trial data of current and novel BTK inhibitors, including monotherapy and combination approaches
- Review strategies for improving patient outcomes, including optimal selection and sequencing of therapy, as well as oral adherence strategies
Activity Description
Bruton’s tyrosine kinase (BTK) inhibitors are an evolving therapeutic strategy for the treatment of patients with CLL. With multiple BTK inhibitors (and combinations) under investigation and pending approval, clinicians need expert guidance to correctly use these agents safely and effectively for patients with CLL, and plan strategies for optimal integration of these novel agents into practice. This webcast will provide expert interpretation of emerging data and guidance regarding patient diagnosis, treatment, maintenance therapy, and sequencing of agents.
Statement of Educational Need
BTK inhibitors have substantially altered the management, clinical course, and outcome of patients with CLL. This is especially true for patients with previously limited treatment options due to disease characteristics or coexisting diseases. Ibrutinib was the first orally available, nonselective and irreversible inhibitor of BTK approved for the treatment of patients with various B-cell malignancies. Newer and more selective BTK inhibitors are currently in clinical development, including acalabrutinib, which is currently US FDA approved for previously treated mantle cell lymphoma. Significant efforts are underway to investigate the optimal combinations, timing, and sequencing of BTK inhibitors with other regimens and targeted agents, and to capitalize on the immunomodulatory modes of action of BTK inhibitors to correct tumor-induced immune defects and to achieve long-lasting tumor control.
Faculty
Associate Professor of Medicine
Harvard Medical Center
Associate Director, Center for Chronic Lymphocytic Leukemia
Dana-Farber Cancer Institute
Boston, Massachusetts
Disclosures
Contracted Research & Publishing: AbbVie Inc., Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma Inc., Pharmacyclics LLC, Surface Oncology, TG Therapeutics, Verastem, Inc.
Consulting Fees: AbbVie Inc., Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Celgene Corporation, Genentech, Janssen, MEI Pharma Inc., Pharmacyclics LLC, Research to Practice, TG Therapeutics, Verastem, Inc.
Conflict of Interest Policy/Disclosure Statement
Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
All disclosed conflicts of interest have been resolved by independent content review.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.
Accreditation Statement
Continuing Education
The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Statement of Commercial Support
This activity is supported by independent educational grants from AstraZeneca, BeiGene and Pharmacyclics.
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Contact Information for Questions About the Activity
info@bioascend.com
Diagnosis and Management of Acquired Methemoglobinemia
StartDiagnosis and Management of Acquired Methemoglobinemia
Activity Details
1.0 Contact Hour(s)
Expires: December 1, 2021
Accredited By
Target Audience
Emergency medicine physicians, intensivists, toxicologists, infectious disease specialists, oncologists, advanced practitioners, nurses, hospital-based pharmacists, and other healthcare professionals involved in the care of patients with acquired methemoglobinemia.
Learning Objectives
- Discuss the pathophysiologic basis of methemoglobinemia, explain the origin of the “saturation gap,” and apply that to diagnostic evaluation
- Analyze available data on the various treatment options for acquired methemoglobinemia
- Develop therapeutic plans and monitor adverse side effects with the multidisciplinary care team to improve patient outcomes
Activity Description
The diagnosis of acquired methemoglobinemia requires a high index of clinical suspicion, confirmation with objective testing, and prompt specific treatment in addition to support. There are important clues to the diagnosis, especially a “saturation gap” between an arterial blood gas and pulse oximetry data, and careful history of drug use or potential toxin exposure. Because acquired methemoglobinemia is rare, clinicians should seek out and pursue education on the most up-to-date information on etiology, diagnosis, and treatment.
Statement of Educational Need
Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with acquired methemoglobinemia.
Agenda
- Patient Case 1 Analysis: An Ill Patient with an Oxygen Saturation Gap
- Pathophysiology of Acquired Methemoglobinemia: Identifying the Usual Suspects, but in Context
- Clinical Strategies to Improve Outcomes in Patients with Acquired Methemoglobinemia
- Patient Case 2 Analysis: Acute Decompensation in the ICU
- An Interprofessional Approach to Treatment Plan Development & Patient Monitoring
Faculty
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi
Executive Director of Pharmacy
Brigham and Women’s Hospital
Boston, Massachusetts
Frank LoVecchio, DO,
MPH, FACEP, ABMTProfessor, Research Scholar, University of Arizona
Emergency Medicine, Medicine and Pharmacology
Tucson, Arizona
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
Charles V. Pollack Jr., MA, MD (Course Chair)
Grant/Research Support: AstraZeneca Pharmaceuticals; PROVEPHARM INC.
Consultant/Advisor: AstraZeneca Pharmaceuticals
John Fanikos, RPh, MBA
Consultant/Advisor: AstraZeneca Pharmaceuticals; Boehringer Ingelheim International GmbH; Portola Therapeutics, Inc.; Ipsen Pharmaceuticals, Inc.
Grant/Research Support: Boehringer Ingelheim International GmbH; Heron Therapeutics, Inc.
Frank LoVecchio, DO, MPH, FACEP, ABMT
Grant/Research Support: National Institutes of Health
Speaker’s Bureau: Allergan
Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.
Designation of Credit
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hours, including 1.0 Pharmacotherapeutic Contact Hours (Provider number P0491).
AcademicCME designates this continuing education activity for 1.0 CPE Contact Hours (0.10 CEUs) of continuing pharmacy education credit (UAN #: JA4008190-0000-20-012-H04-P).
Participants should claim only the credit commensurate with the extent of their participation in the activity.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions.
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 70% or better on the Post-Activity Test
Questions and complete the Evaluation will receive appropriate credit as
indicated (CME, CNE, and/or CPE credit).
CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
CME and CNE credit will be issued appropriate certificate of completion.
Others may request a "certificate of completion". - Learners should claim only the credit commensurate with the extent of their participation in the activity.
Statement of Commercial Support
This activity has been supported by an independent educational grant from PROVEPHARM INC.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and PROVEPHARM INC. do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.
Diagnosis and Management of Acquired Methemoglobinemia
Activity Details
1.0 Contact Hour(s)
Expires: December 1, 2021
Accredited By
Target Audience
Emergency medicine physicians, intensivists, toxicologists, infectious disease specialists, oncologists, advanced practitioners, nurses, hospital-based pharmacists, and other healthcare professionals involved in the care of patients with acquired methemoglobinemia.
Learning Objectives
- Discuss the pathophysiologic basis of methemoglobinemia, explain the origin of the “saturation gap,” and apply that to diagnostic evaluation
- Analyze available data on the various treatment options for acquired methemoglobinemia
- Develop therapeutic plans and monitor adverse side effects with the multidisciplinary care team to improve patient outcomes
Activity Description
The diagnosis of acquired methemoglobinemia requires a high index of clinical suspicion, confirmation with objective testing, and prompt specific treatment in addition to support. There are important clues to the diagnosis, especially a “saturation gap” between an arterial blood gas and pulse oximetry data, and careful history of drug use or potential toxin exposure. Because acquired methemoglobinemia is rare, clinicians should seek out and pursue education on the most up-to-date information on etiology, diagnosis, and treatment.
Statement of Educational Need
Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with acquired methemoglobinemia.
Agenda
- Patient Case 1 Analysis: An Ill Patient with an Oxygen Saturation Gap
- Pathophysiology of Acquired Methemoglobinemia: Identifying the Usual Suspects, but in Context
- Clinical Strategies to Improve Outcomes in Patients with Acquired Methemoglobinemia
- Patient Case 2 Analysis: Acute Decompensation in the ICU
- An Interprofessional Approach to Treatment Plan Development & Patient Monitoring
Faculty
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi
Executive Director of Pharmacy
Brigham and Women’s Hospital
Boston, Massachusetts
Frank LoVecchio, DO,
MPH, FACEP, ABMTProfessor, Research Scholar, University of Arizona
Emergency Medicine, Medicine and Pharmacology
Tucson, Arizona
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
Charles V. Pollack Jr., MA, MD (Course Chair)
Grant/Research Support: AstraZeneca Pharmaceuticals; PROVEPHARM INC.
Consultant/Advisor: AstraZeneca Pharmaceuticals
John Fanikos, RPh, MBA
Consultant/Advisor: AstraZeneca Pharmaceuticals; Boehringer Ingelheim International GmbH; Portola Therapeutics, Inc.; Ipsen Pharmaceuticals, Inc.
Grant/Research Support: Boehringer Ingelheim International GmbH; Heron Therapeutics, Inc.
Frank LoVecchio, DO, MPH, FACEP, ABMT
Grant/Research Support: National Institutes of Health
Speaker’s Bureau: Allergan
Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.
Designation of Credit
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hours, including 1.0 Pharmacotherapeutic Contact Hours (Provider number P0491).
AcademicCME designates this continuing education activity for 1.0 CPE Contact Hours (0.10 CEUs) of continuing pharmacy education credit (UAN #: JA4008190-0000-20-012-H04-P).
Participants should claim only the credit commensurate with the extent of their participation in the activity.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions.
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 70% or better on the Post-Activity Test
Questions and complete the Evaluation will receive appropriate credit as
indicated (CME, CNE, and/or CPE credit).
CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
CME and CNE credit will be issued appropriate certificate of completion.
Others may request a "certificate of completion". - Learners should claim only the credit commensurate with the extent of their participation in the activity.
Statement of Commercial Support
This activity has been supported by an independent educational grant from PROVEPHARM INC.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and PROVEPHARM INC. do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.
The Expanding Treatment Landscape of Waldenström’s Macroglobulinemia
StartActivity Details
1.0 Contact Hour(s)
Expires: October 27, 2021
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Waldenström’s Macroglobulinemia.
Learning Objectives
After completing this program, participants should be able to:
- Summarize criteria required to accurately diagnose patients with Waldenström’s macroglobulinemia and identify those most likely to benefit from treatment
- Evaluate the latest clinical data on the efficacy and safety of approved and investigational therapies for patients with Waldenström’s macroglobulinemia
- Formulate best-practice treatment strategies for patients with Waldenström’s macroglobulinemia, taking into consideration current guidelines and expert recommendations when individualizing treatment plans
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of Waldenström’s Macroglobulinemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
With the recent advances in targeted therapies for WM, the use of approved and investigational agents is anticipated to expand over the coming years. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate diagnosis and risk stratification of patients with WM and the clinical utility of agents that could significantly impact patient outcomes.
Faculty
Director, Bing Center for Waldenström's Macroglobulinemia
Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA
Conflict of Interest Policy/Disclosure Statement
Dr. Treon has consulted for Janssen Pharmaceuticals, Inc., Pharmacyclics, Inc., and BeiGene, Inc.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only credit commensurate with the extent of their
participation in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of 1.0 continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of 1.0 continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by an educational grant from Janssen Biotech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Activity Details
1.0 Contact Hour(s)
Expires: October 27, 2021
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Waldenström’s Macroglobulinemia.
Learning Objectives
After completing this program, participants should be able to:
- Summarize criteria required to accurately diagnose patients with Waldenström’s macroglobulinemia and identify those most likely to benefit from treatment
- Evaluate the latest clinical data on the efficacy and safety of approved and investigational therapies for patients with Waldenström’s macroglobulinemia
- Formulate best-practice treatment strategies for patients with Waldenström’s macroglobulinemia, taking into consideration current guidelines and expert recommendations when individualizing treatment plans
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of Waldenström’s Macroglobulinemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
With the recent advances in targeted therapies for WM, the use of approved and investigational agents is anticipated to expand over the coming years. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate diagnosis and risk stratification of patients with WM and the clinical utility of agents that could significantly impact patient outcomes.
Faculty
Director, Bing Center for Waldenström's Macroglobulinemia
Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA
Conflict of Interest Policy/Disclosure Statement
Dr. Treon has consulted for Janssen Pharmaceuticals, Inc., Pharmacyclics, Inc., and BeiGene, Inc.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only credit commensurate with the extent of their
participation in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of 1.0 continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of 1.0 continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by an educational grant from Janssen Biotech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Advances in Hemophilia A: Coordinating Care Through Effective Communication and Therapy Selection
StartActivity Details
Expires: October 7, 2021
Accredited By
This continuing nurse education activity is provided by
Target Audience
The intended audience for this activity is registered nurses (RNs), nurse practitioners (NPs), oncology RNs, oncology NPs, hemophilia RNs, hemophilia NPs, hemophilia treatment center RNs, hemophilia treatment center NPs, and other health care professionals involved in the management of patients with hemophilia A.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Assess the latest evidence regarding treatments for patients with hemophilia A that may reduce treatment burden and enhance quality of life.
- Identify patients with hemophilia A without factor VIII inhibitors who may benefit from newer treatment options.
- Review strategies for educating patients with hemophilia A about their disease state and treatment options to facilitate the use of shared decision-making and improve patient satisfaction.
Activity Description
Hemophilia A is an X-linked recessive disease primarily affecting men, with an estimated 20,000 individuals in the United States having the disease. Disease severity is related to the degree to which factor VIII (FVIII) levels are reduced, with patients often requiring multiple infusions a week. Newer approaches to treating hemophilia A include extended half-life FVIII products that allow for reduced dosing, as well as emicizumab, a bispecific antibody therapy that mimics the cofactor activity of factor VIII by binding to and bridging activated factor IX and factor X. Given recent developments that include new drug approvals, expanded drug indications, and self-administration options, education is needed to keep clinicians apprised of best practices for managing hemophilia A in patients with and without inhibitors. In this CNE activity, expert faculty examine the latest evidence regarding new and emerging treatments for patients with hemophilia A and provide guidance on identifying patients with and without factor VIII inhibitors who may benefit from newer treatment options. Additionally, faculty will discuss strategies to promote shared decision-making and improve patient satisfaction.
Agenda
Introduction and Background
Regina B. Butler, RN-BC
Advances in the Management of Patients With Hemophilia A – Differentiating
Options
Kerry Hansen, RN-BC
Optimizing Communication, Patient Education, and Shared Decision-Making in
Patients With Hemophilia A
James E. Munn, MS, BS, BSN, RN-BC
Faculty
Activity Chair:
Director, Mid-Atlantic/Region III Hemophilia Treatment Centers
Clinical Manager, Division of Hematology
Children's Hospital of Philadelphia
Philadelphia, PA
Disclosure:
Consulting Fee: Genentech, Pfizer
Faculty:
Nurse Clinician
M Health Fairview
University of Minnesota
Minneapolis, MN
Disclosure: No relevant financial relationships to disclose.
Program Nurse Coordinator
University of Michigan Medical Center
Ann Arbor, MI
Disclosure:
Consulting Fee: Bayer, Sanofi Genzyme
Advisory Board: CSL Behring, Genentech, Novo Nordisk, Octapharma, Takeda
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Barbara A. Niedz, PhD, RN, CPHQ
Disclosure:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the American Nurses Credentialing Center’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
Designation of Credit
Vindico Medical Education will provide a maximum of 0.75 contact hour for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
This activity is approved for
0.75 contact hour(s) of continuing education by the American Association of
Nurse Practitioners. Activity ID 20094522. This activity was planned in
accordance with AANP Accreditation Standards and Policies.
Instructions for Receiving Credit
To participate in this CNE activity, you must read the objectives, answer the pretest questions, view the CNE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue a Contact Hours Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
There is no non-commercial support for this activity.
Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CNE Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: October 7, 2021
Accredited By
This continuing nurse education activity is provided by
Target Audience
The intended audience for this activity is registered nurses (RNs), nurse practitioners (NPs), oncology RNs, oncology NPs, hemophilia RNs, hemophilia NPs, hemophilia treatment center RNs, hemophilia treatment center NPs, and other health care professionals involved in the management of patients with hemophilia A.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Assess the latest evidence regarding treatments for patients with hemophilia A that may reduce treatment burden and enhance quality of life.
- Identify patients with hemophilia A without factor VIII inhibitors who may benefit from newer treatment options.
- Review strategies for educating patients with hemophilia A about their disease state and treatment options to facilitate the use of shared decision-making and improve patient satisfaction.
Activity Description
Hemophilia A is an X-linked recessive disease primarily affecting men, with an estimated 20,000 individuals in the United States having the disease. Disease severity is related to the degree to which factor VIII (FVIII) levels are reduced, with patients often requiring multiple infusions a week. Newer approaches to treating hemophilia A include extended half-life FVIII products that allow for reduced dosing, as well as emicizumab, a bispecific antibody therapy that mimics the cofactor activity of factor VIII by binding to and bridging activated factor IX and factor X. Given recent developments that include new drug approvals, expanded drug indications, and self-administration options, education is needed to keep clinicians apprised of best practices for managing hemophilia A in patients with and without inhibitors. In this CNE activity, expert faculty examine the latest evidence regarding new and emerging treatments for patients with hemophilia A and provide guidance on identifying patients with and without factor VIII inhibitors who may benefit from newer treatment options. Additionally, faculty will discuss strategies to promote shared decision-making and improve patient satisfaction.
Agenda
Introduction and Background
Regina B. Butler, RN-BC
Advances in the Management of Patients With Hemophilia A – Differentiating
Options
Kerry Hansen, RN-BC
Optimizing Communication, Patient Education, and Shared Decision-Making in
Patients With Hemophilia A
James E. Munn, MS, BS, BSN, RN-BC
Faculty
Activity Chair:
Director, Mid-Atlantic/Region III Hemophilia Treatment Centers
Clinical Manager, Division of Hematology
Children's Hospital of Philadelphia
Philadelphia, PA
Disclosure:
Consulting Fee: Genentech, Pfizer
Faculty:
Nurse Clinician
M Health Fairview
University of Minnesota
Minneapolis, MN
Disclosure: No relevant financial relationships to disclose.
Program Nurse Coordinator
University of Michigan Medical Center
Ann Arbor, MI
Disclosure:
Consulting Fee: Bayer, Sanofi Genzyme
Advisory Board: CSL Behring, Genentech, Novo Nordisk, Octapharma, Takeda
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Barbara A. Niedz, PhD, RN, CPHQ
Disclosure:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the American Nurses Credentialing Center’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
Designation of Credit
Vindico Medical Education will provide a maximum of 0.75 contact hour for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
This activity is approved for
0.75 contact hour(s) of continuing education by the American Association of
Nurse Practitioners. Activity ID 20094522. This activity was planned in
accordance with AANP Accreditation Standards and Policies.
Instructions for Receiving Credit
To participate in this CNE activity, you must read the objectives, answer the pretest questions, view the CNE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue a Contact Hours Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
There is no non-commercial support for this activity.
Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CNE Questions?
Contact us at CME@VindicoCME.com
Expert Insights: The Expanding Role of Immunotherapy for the Treatment of Multiple Myeloma - Focus on Antibodies, Antibody-Drug Conjugates, and CAR T-Cells
StartActivity Details
Expires: August 3, 2021
Accredited By
The University of Nebraska Medical Center, Center for Continuing Education
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.
Learning Objectives
After participating in this activity, participants should be better able to:
- Review unmet needs in the care of multiple myeloma (MM) and the potential role of immunotherapies such as antibodies, antibody-drug conjugates, CAR T-cells, and others
- Evaluate clinical trial data of current and emerging immunotherapies being examined in patients with MM
- Assess unique adverse event profiles of immunotherapies that differ from traditional therapies used for the treatment of patients with MM
- Develop strategies to integrate immunotherapies into the MM treatment paradigm as they become available
Activity Description
Expert Insights is a summary of a virtual satellite symposium from the 2020 Clinical Oncology Meeting and will discuss current data of current and emerging immunotherapeutic-based approaches for the treatment of patients with multiple myeloma.
Statement of Educational Need
Given the recent approval of immunotherapies for the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with MM.
Agenda
- Unmet needs
- Monoclonal antibodies
- BiTEs
- Vaccines
- ADCs
- CAR T-cells
Faculty
Chief, Plasma Cell Disorders Division
Director, Clinical Research in Hematologic Malignancies
Department of Hematologic Oncology & Blood Disorders
Levine Cancer Institute
Charlotte, North Carolina
Consulting Fees: Amgen Inc., Bristol Myers Squibb, Celgene Corporation, GlaxoSmithKline, Janssen Oncology, Merck & Co., Sanofi, SkylineDX, Takeda Pharmaceutical Company
Contracted Research & Publishing: Amgen Inc., Array BioPharma, Bristol Myers Squibb, Celgene Corporation, GlaxoSmithKline, Janssen Oncology, Merck & Co., Pharmacyclics LLC, Sanofi, Seattle Genetics, SkylineDX, Takeda Pharmaceutical Company
Speaker’s Bureau: Amgen Inc., Celgene Corporation, Janssen Oncology, Sanofi, Takeda Pharmaceutical Company
Assistant Professor
Department of Lymphoma and Myeloma
Assistant Professor
Department of Stem Cell Transplantation
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Consulting Fees: Bristol Myers Squibb, Celgene Corporation, Cellectis, Janssen Oncology, Nektar Therapeutics, Pfizer Inc., Poseida Therapeutics, Inc., Precision BioSciences
Contracted Research & Publishing: AbbVie Inc., Bristol Myers Squibb, Celgene Corporation, Cellectis, Janssen Oncology, Nektar Therapeutics, Poseida Therapeutics, Inc., Precision BioSciences
Conflict of Interest Policy/Disclosure Statement
Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the UNMC Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.
Accreditation Statement
Continuing Education
The University of Nebraska Medical Center (UNMC), Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The UNMC Center for Continuing Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of the UNMC Center for Continuing Education and Bio Ascend.
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Materials will be available online through August 3, 2021.
Statement of Commercial Support
This activity is supported by independent educational grants from Legend Biotech and Sanofi Genzyme.
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Contact Information for Questions About the Activity
cme@bioascend.com
Activity Details
Expires: August 3, 2021
Accredited By
The University of Nebraska Medical Center, Center for Continuing Education
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.
Learning Objectives
After participating in this activity, participants should be better able to:
- Review unmet needs in the care of multiple myeloma (MM) and the potential role of immunotherapies such as antibodies, antibody-drug conjugates, CAR T-cells, and others
- Evaluate clinical trial data of current and emerging immunotherapies being examined in patients with MM
- Assess unique adverse event profiles of immunotherapies that differ from traditional therapies used for the treatment of patients with MM
- Develop strategies to integrate immunotherapies into the MM treatment paradigm as they become available
Activity Description
Expert Insights is a summary of a virtual satellite symposium from the 2020 Clinical Oncology Meeting and will discuss current data of current and emerging immunotherapeutic-based approaches for the treatment of patients with multiple myeloma.
Statement of Educational Need
Given the recent approval of immunotherapies for the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with MM.
Agenda
- Unmet needs
- Monoclonal antibodies
- BiTEs
- Vaccines
- ADCs
- CAR T-cells
Faculty
Chief, Plasma Cell Disorders Division
Director, Clinical Research in Hematologic Malignancies
Department of Hematologic Oncology & Blood Disorders
Levine Cancer Institute
Charlotte, North Carolina
Consulting Fees: Amgen Inc., Bristol Myers Squibb, Celgene Corporation, GlaxoSmithKline, Janssen Oncology, Merck & Co., Sanofi, SkylineDX, Takeda Pharmaceutical Company
Contracted Research & Publishing: Amgen Inc., Array BioPharma, Bristol Myers Squibb, Celgene Corporation, GlaxoSmithKline, Janssen Oncology, Merck & Co., Pharmacyclics LLC, Sanofi, Seattle Genetics, SkylineDX, Takeda Pharmaceutical Company
Speaker’s Bureau: Amgen Inc., Celgene Corporation, Janssen Oncology, Sanofi, Takeda Pharmaceutical Company
Assistant Professor
Department of Lymphoma and Myeloma
Assistant Professor
Department of Stem Cell Transplantation
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Consulting Fees: Bristol Myers Squibb, Celgene Corporation, Cellectis, Janssen Oncology, Nektar Therapeutics, Pfizer Inc., Poseida Therapeutics, Inc., Precision BioSciences
Contracted Research & Publishing: AbbVie Inc., Bristol Myers Squibb, Celgene Corporation, Cellectis, Janssen Oncology, Nektar Therapeutics, Poseida Therapeutics, Inc., Precision BioSciences
Conflict of Interest Policy/Disclosure Statement
Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the UNMC Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.
Accreditation Statement
Continuing Education
The University of Nebraska Medical Center (UNMC), Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The UNMC Center for Continuing Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of the UNMC Center for Continuing Education and Bio Ascend.
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Materials will be available online through August 3, 2021.
Statement of Commercial Support
This activity is supported by independent educational grants from Legend Biotech and Sanofi Genzyme.
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Contact Information for Questions About the Activity
cme@bioascend.com
Optimizing Treatment of B-Cell Non-Hodgkin Lymphomas in the Modern Era - Part B
StartActivity Details
0.5 Contact Hour(s)
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with B-Cell Non-Hodgkin Lymphomas.
Learning Objectives
After completing this program, participants should be able to:
- Summarize current evidence-based management strategies for treating B-cell NHLs with newer agents and combination approaches
- Evaluate safety and efficacy data from recent clinical trials and its impact on future clinical practice
- Formulate individualized strategies for incorporating new agents and regimens into the evolving treatment paradigms for B-cell NHLs, taking into consideration current guidelines, expert recommendations, and clinical factors
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of B-Cell Non-Hodgkin Lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for B-Cell Non-Hodgkin Lymphomas along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with B-Cell Non-Hodgkin Lymphomas, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Co-Director Lymphoma Program
Winship Cancer Institute
Emory University
Atlanta, GA
Conflict of Interest Policy/Disclosure Statement
Dr. Cohen has served on advisory boards for Janssen and Genentech and has done research funding for Genentech.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by educational grant from AbbVie Inc., Bayer HealthCare Pharmaceutical Inc., Celgene Corp., Janssen Biotech, Inc., and Verastem.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions about the Activity
Activity Details
0.5 Contact Hour(s)
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with B-Cell Non-Hodgkin Lymphomas.
Learning Objectives
After completing this program, participants should be able to:
- Summarize current evidence-based management strategies for treating B-cell NHLs with newer agents and combination approaches
- Evaluate safety and efficacy data from recent clinical trials and its impact on future clinical practice
- Formulate individualized strategies for incorporating new agents and regimens into the evolving treatment paradigms for B-cell NHLs, taking into consideration current guidelines, expert recommendations, and clinical factors
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of B-Cell Non-Hodgkin Lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for B-Cell Non-Hodgkin Lymphomas along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with B-Cell Non-Hodgkin Lymphomas, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Co-Director Lymphoma Program
Winship Cancer Institute
Emory University
Atlanta, GA
Conflict of Interest Policy/Disclosure Statement
Dr. Cohen has served on advisory boards for Janssen and Genentech and has done research funding for Genentech.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by educational grant from AbbVie Inc., Bayer HealthCare Pharmaceutical Inc., Celgene Corp., Janssen Biotech, Inc., and Verastem.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions about the Activity
Optimizing Treatment of B-Cell Non-Hodgkin Lymphomas in the Modern Era - Part A
StartActivity Details
0.5 Contact Hour(s)
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with B-Cell Non-Hodgkin Lymphomas.
Learning Objectives
After completing this program, participants should be able to:
- Summarize current evidence-based management strategies for treating B-cell NHLs with newer agents and combination approaches
- Evaluate safety and efficacy data from recent clinical trials and its impact on future clinical practice
- Formulate individualized strategies for incorporating new agents and regimens into the evolving treatment paradigms for B-cell NHLs, taking into consideration current guidelines, expert recommendations, and clinical factors
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of B-Cell Non-Hodgkin Lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for B-Cell Non-Hodgkin Lymphomas along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with B-Cell Non-Hodgkin Lymphomas, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Co-Director Lymphoma Program
Winship Cancer Institute
Emory University
Atlanta, GA
Conflict of Interest Policy/Disclosure Statement
Dr. Cohen has served on advisory boards for Janssen and Genentech and has done research funding for Genentech.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by educational grant from AbbVie Inc., Bayer HealthCare Pharmaceutical Inc., Celgene Corp., Janssen Biotech, Inc., and Verastem.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions about the Activity
Activity Details
0.5 Contact Hour(s)
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with B-Cell Non-Hodgkin Lymphomas.
Learning Objectives
After completing this program, participants should be able to:
- Summarize current evidence-based management strategies for treating B-cell NHLs with newer agents and combination approaches
- Evaluate safety and efficacy data from recent clinical trials and its impact on future clinical practice
- Formulate individualized strategies for incorporating new agents and regimens into the evolving treatment paradigms for B-cell NHLs, taking into consideration current guidelines, expert recommendations, and clinical factors
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of B-Cell Non-Hodgkin Lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for B-Cell Non-Hodgkin Lymphomas along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with B-Cell Non-Hodgkin Lymphomas, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Co-Director Lymphoma Program
Winship Cancer Institute
Emory University
Atlanta, GA
Conflict of Interest Policy/Disclosure Statement
Dr. Cohen has served on advisory boards for Janssen and Genentech and has done research funding for Genentech.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by educational grant from AbbVie Inc., Bayer HealthCare Pharmaceutical Inc., Celgene Corp., Janssen Biotech, Inc., and Verastem.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.